The Alzheimer's development crisis: here's how we must change
This article was originally published in Scrip
Executive Summary
Dimebon (latrepirdine) is dead. It didn’t come as much of a shock when Pfizer and Medivation discontinued development of the compound for Alzheimer’s disease treatment. Hope had already significantly faded for Dimebon’s potential and success in Alzheimer’s over the past few years. But the finality of even this underwhelming programme highlights a creeping gloom.